Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance

Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food supplements are widely used by people living with cancer. These products are predominantly self-selected and taken concurrently with cancer treatments with the intention of improvin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer chemotherapy and pharmacology Jg. 91; H. 2; S. 103 - 119
Hauptverfasser: Chan, Wai-Jo Jocelin, Adiwidjaja, Jeffry, McLachlan, Andrew J., Boddy, Alan V., Harnett, Joanna E.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2023
Springer Nature B.V
Schlagworte:
Biological Products
Cancer
Cancer Research
Cancer therapies
Clinical outcomes
Clinical Relevance
Curcuma longa
Diarrhea
Dietary Supplements
Drug-Related Side Effects and Adverse Reactions
grapefruits
Herb-Drug Interactions
Humans
Hydrastis canadensis
Hypericum perforatum
Immune response
Medicine
Medicine & Public Health
Mucositis
Natural products
Neoplasms
Oncology
Pharmacodynamics
Pharmacokinetics
Pharmacology/Toxicology
Quality of Life
Review
Review Article
Schisandra
Side effects
Chemotherapy
Interactions
Natural products
Complementary medicines
Herbal medicines
Cancer
ISSN:0344-5704, 1432-0843, 1432-0843
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food supplements are widely used by people living with cancer. These products are predominantly self-selected and taken concurrently with cancer treatments with the intention of improving quality of life, immune function and reducing cancer symptoms and treatment side effects. Concerns have been raised that concurrent use may lead to interactions resulting in adverse effects and unintended treatment outcomes. This review provides an overview of the mechanisms by which these interactions can occur and the current evidence about specific clinically important natural product–drug interactions. Clinical studies investigating pharmacokinetic interactions provide evidence that negative treatment outcomes may occur when Hypericum perforatum , Grapefruit, Schisandra sphenanthera, Curcuma longa or Hydrastis canadensis are taken concurrently with common cancer treatments. Conversely, pharmacodynamic interactions between Hangeshashinto (TJ-14) and some cancer treatments have been shown to reduce the side effects of diarrhoea and oral mucositis. In summary, research in this area is limited and requires further investigation.
AbstractList Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food supplements are widely used by people living with cancer. These products are predominantly self-selected and taken concurrently with cancer treatments with the intention of improving quality of life, immune function and reducing cancer symptoms and treatment side effects. Concerns have been raised that concurrent use may lead to interactions resulting in adverse effects and unintended treatment outcomes. This review provides an overview of the mechanisms by which these interactions can occur and the current evidence about specific clinically important natural product–drug interactions. Clinical studies investigating pharmacokinetic interactions provide evidence that negative treatment outcomes may occur when Hypericum perforatum, Grapefruit, Schisandra sphenanthera, Curcuma longa or Hydrastis canadensis are taken concurrently with common cancer treatments. Conversely, pharmacodynamic interactions between Hangeshashinto (TJ-14) and some cancer treatments have been shown to reduce the side effects of diarrhoea and oral mucositis. In summary, research in this area is limited and requires further investigation.
Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food supplements are widely used by people living with cancer. These products are predominantly self-selected and taken concurrently with cancer treatments with the intention of improving quality of life, immune function and reducing cancer symptoms and treatment side effects. Concerns have been raised that concurrent use may lead to interactions resulting in adverse effects and unintended treatment outcomes. This review provides an overview of the mechanisms by which these interactions can occur and the current evidence about specific clinically important natural product–drug interactions. Clinical studies investigating pharmacokinetic interactions provide evidence that negative treatment outcomes may occur when Hypericum perforatum , Grapefruit, Schisandra sphenanthera, Curcuma longa or Hydrastis canadensis are taken concurrently with common cancer treatments. Conversely, pharmacodynamic interactions between Hangeshashinto (TJ-14) and some cancer treatments have been shown to reduce the side effects of diarrhoea and oral mucositis. In summary, research in this area is limited and requires further investigation.
Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food supplements are widely used by people living with cancer. These products are predominantly self-selected and taken concurrently with cancer treatments with the intention of improving quality of life, immune function and reducing cancer symptoms and treatment side effects. Concerns have been raised that concurrent use may lead to interactions resulting in adverse effects and unintended treatment outcomes. This review provides an overview of the mechanisms by which these interactions can occur and the current evidence about specific clinically important natural product-drug interactions. Clinical studies investigating pharmacokinetic interactions provide evidence that negative treatment outcomes may occur when Hypericum perforatum, Grapefruit, Schisandra sphenanthera, Curcuma longa or Hydrastis canadensis are taken concurrently with common cancer treatments. Conversely, pharmacodynamic interactions between Hangeshashinto (TJ-14) and some cancer treatments have been shown to reduce the side effects of diarrhoea and oral mucositis. In summary, research in this area is limited and requires further investigation.Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food supplements are widely used by people living with cancer. These products are predominantly self-selected and taken concurrently with cancer treatments with the intention of improving quality of life, immune function and reducing cancer symptoms and treatment side effects. Concerns have been raised that concurrent use may lead to interactions resulting in adverse effects and unintended treatment outcomes. This review provides an overview of the mechanisms by which these interactions can occur and the current evidence about specific clinically important natural product-drug interactions. Clinical studies investigating pharmacokinetic interactions provide evidence that negative treatment outcomes may occur when Hypericum perforatum, Grapefruit, Schisandra sphenanthera, Curcuma longa or Hydrastis canadensis are taken concurrently with common cancer treatments. Conversely, pharmacodynamic interactions between Hangeshashinto (TJ-14) and some cancer treatments have been shown to reduce the side effects of diarrhoea and oral mucositis. In summary, research in this area is limited and requires further investigation.
Author Boddy, Alan V.
Chan, Wai-Jo Jocelin
McLachlan, Andrew J.
Harnett, Joanna E.
Adiwidjaja, Jeffry
Author_xml – sequence: 1
  givenname: Wai-Jo Jocelin
  surname: Chan
  fullname: Chan, Wai-Jo Jocelin
  organization: Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney
– sequence: 2
  givenname: Jeffry
  surname: Adiwidjaja
  fullname: Adiwidjaja, Jeffry
  organization: Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina
– sequence: 3
  givenname: Andrew J.
  surname: McLachlan
  fullname: McLachlan, Andrew J.
  organization: Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney
– sequence: 4
  givenname: Alan V.
  surname: Boddy
  fullname: Boddy, Alan V.
  organization: Clinical and Health Sciences, University of South Australia
– sequence: 5
  givenname: Joanna E.
  orcidid: 0000-0001-9904-2144
  surname: Harnett
  fullname: Harnett, Joanna E.
  email: joanna.harnett@sydney.edu.au
  organization: Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36707434$$D View this record in MEDLINE/PubMed
BookMark eNqFks1u1DAUhS1URKcDL8ACRWLDJnATO7HNAglV_FSq1E1ZWx77ZupRYg-2U9Q-PR5mCm0XRbLkhb9zdK7vOSFHPngk5HUD7xsA_iEBtAJqaGkNrANW3z4ji4bRtgbB6BFZAGWs7jiwY3KS0gYAWEPpC3JMew6cUbYgmzOfMWqTXfCpWmH-hegrr_Mc9VhtY7CzyanS3lZGe4OxyhF1ntDn9LGavcU43ji_riY0V9q7NB3g0XlnioWbtiHmnfQleT7oMeGrw70kP75-uTz9Xp9ffDs7_Xxemw54rm0rtbVtj0IYaTs-UC6gZbphK9Z3RvfY2zIu9kMBxdAMhe0ZGLMaoLGmp0vyae-7nVcTWlOillnUNrpJxxsVtFMPX7y7UutwraSErpGyGLw7GMTwc8aU1eSSwXHUHsOcVCuYFIKX83-Ul9_nsuQt6NtH6CbM0Zef2FFUyr4ru1uSN_fD_019t7ECiD1gYkgp4qCMy3q3vjKLG1UDalcOtS-HKuVQf8qhbou0fSS9c39SRPeiVGC_xvgv9hOq3440z0E
CitedBy_id crossref_primary_10_1016_j_soncn_2025_151816
crossref_primary_10_1002_jssc_202300923
crossref_primary_10_1089_can_2023_0284
crossref_primary_10_3390_ijms242115976
crossref_primary_10_1002_cpt_3547
crossref_primary_10_3390_cancers16183130
crossref_primary_10_1097_NSG_0000000000000078
crossref_primary_10_3390_jcm13051190
crossref_primary_10_1016_j_drup_2023_101004
crossref_primary_10_1371_journal_pone_0329490
crossref_primary_10_3390_molecules29194711
crossref_primary_10_1080_14786419_2025_2513583
crossref_primary_10_1152_ajpcell_00176_2024
crossref_primary_10_1177_10915818251345116
crossref_primary_10_1002_jbt_70189
crossref_primary_10_1186_s40360_025_00836_z
crossref_primary_10_3390_molecules29174066
crossref_primary_10_1016_j_jep_2025_120391
crossref_primary_10_3390_ijms241210120
crossref_primary_10_1016_j_jep_2023_116575
crossref_primary_10_1007_s13165_024_00477_2
crossref_primary_10_3389_fphar_2023_1257018
crossref_primary_10_2174_0109298673343133241011072425
crossref_primary_10_3390_cancers15113009
crossref_primary_10_1080_13543776_2023_2265561
crossref_primary_10_3390_ph17030336
crossref_primary_10_1186_s13020_025_01156_4
crossref_primary_10_3390_ijms26189118
crossref_primary_10_1016_j_taap_2025_117498
crossref_primary_10_1007_s11095_023_03590_1
crossref_primary_10_56294_hl2025856
crossref_primary_10_1007_s43440_024_00652_y
Cites_doi 10.1517/17425247.2014.865014
10.2147/ott.S145613
10.1177/107327480200900307
10.3390/cancers11030403
10.1002/cpdd.339
10.1192/pb.25.7.254
10.1111/jphp.12858
10.1124/dmd.121.000476
10.1590/S0102-695X2013005000018
10.1111/j.1365-2125.2007.02922.x
10.1002/cpt.1434
10.1080/17425255.2017.1360279
10.2174/138920009788897975
10.1007/s00280-003-0585-0
10.1016/s0140-6736(03)14186-4
10.1016/j.clpt.2004.06.007
10.1016/s0041-1345(03)00211-2
10.1007/s002280050674
10.1007/s11655-015-2146-x
10.2174/138920005774330639
10.1007/s00280-014-2440-x
10.1177/0091270010374472
10.1007/s10549-009-0321-5
10.1200/jco.2012.44.2806
10.2174/0929867043365198
10.1007/978-1-349-14416-7_11
10.1111/j.1476-5381.2011.01672.x
10.1016/j.clcc.2011.03.003
10.1038/s41397-019-0122-0
10.1111/bcp.12159
10.1002/onco.13582
10.1016/j.biopha.2022.113101
10.1126/scitranslmed.3001270
10.1016/j.ctrv.2008.07.003
10.1111/bph.14936
10.3390/nu11102376
10.1200/JCO.2005.03.9800
10.1146/annurev-pharmtox-010716-105010
10.2165/00003088-200342010-00003
10.1016/s0928-0987(03)00200-8
10.1124/dmd.113.055236
10.1124/dmd.117.075408
10.1007/s00280-015-2767-y
10.1067/mcp.2000.112240
10.1093/ajcn/83.5.1097
10.1016/j.jfda.2015.01.009
10.1158/1078-0432.CCR-06-0388
10.1002/1097-0142(19910101)67:1+<319::AID-CNCR2820671319>3.0.CO;2-D
10.1111/jcpt.13493
10.1016/j.hermed.2018.09.004
10.1111/j.1743-7563.2010.01329.x
10.1158/1078-0432.CCR-05-1288
10.1046/j.1365-2125.1998.00764.x
10.1634/theoncologist.12-3-291
10.1177/0091270009336137
10.1007/s40262-013-0102-5
10.1111/bcpt.12914
10.1097/FPC.0b013e3283656bc1
10.1080/01635580701308083
10.1007/s005209900111
10.1016/j.clpt.2005.01.009
10.1111/imj.13534
10.1002/bdd.2312
10.1016/j.leukres.2010.09.014
10.1007/s00280-010-1367-0
10.1038/sj.clpt.6100222
10.1142/s0192415x21500749
10.1124/pharmrev.120.000106
10.1097/fpc.0b013e32834300cc
10.1124/dmd.120.091041
10.1093/jnci/94.16.1247
10.1139/y2012-080
10.1177/0091270003256059
10.1007/s00520-014-2315-z
10.1007/s00280-005-0053-0
10.1592/phco.24.16.1508.50958
10.1124/dmd.119.089615
10.1007/s00228-002-0495-9
10.1093/jncimonographs/lgh026
10.1007/s10549-020-05829-6
10.1038/clpt.2012.159
10.1111/cts.13250
10.1158/1078-0432.Ccr-12-0110
10.1016/s1470-2045(13)70604-1
10.1124/dmd.117.076737
10.1016/j.phrs.2020.105085
10.1093/jnci/djt181
10.1186/2193-1801-2-126
10.2165/00003088-200645030-00002
10.2165/00003088-200544090-00001
10.1046/j.1365-2125.2003.01810.x
10.1155/2013/964592
10.1124/pr.55.3.1
10.1177/1534735416684014
10.7150/jca.24733
ContentType Journal Article
Copyright The Author(s) 2023. , corrected publication 2023
2023. The Author(s).
The Author(s) 2023. , corrected publication 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: The Author(s) 2023. , corrected publication 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. , corrected publication 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
5PM
DOI 10.1007/s00280-023-04504-z
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList Oncogenes and Growth Factors Abstracts
CrossRef


MEDLINE
AGRICOLA
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-0843
EndPage 119
ExternalDocumentID PMC9905199
36707434
10_1007_s00280_023_04504_z
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
-53
-56
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
1N0
1SB
2.D
203
28-
29B
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
6PF
78A
7X7
88E
8AO
8C1
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDYV
AFEXP
AFFNX
AFJLC
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M4Y
MA-
MK0
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SBL
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
Y6R
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
~EX
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFFHD
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
7S9
L.6
PUEGO
5PM
ID FETCH-LOGICAL-c507t-d29add26e88c9d57f378024a14b465ca6e6d045e6f29a8f1fd26640ccbf01dc63
IEDL.DBID 8C1
ISICitedReferencesCount 43
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000920951000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0344-5704
1432-0843
IngestDate Tue Nov 04 02:07:13 EST 2025
Fri Sep 05 14:22:43 EDT 2025
Sun Nov 09 13:17:22 EST 2025
Sat Nov 08 15:50:38 EST 2025
Wed Feb 19 02:24:48 EST 2025
Tue Nov 18 22:23:55 EST 2025
Sat Nov 29 04:45:40 EST 2025
Fri Feb 21 02:44:42 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Chemotherapy
Interactions
Natural products
Complementary medicines
Herbal medicines
Cancer
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c507t-d29add26e88c9d57f378024a14b465ca6e6d045e6f29a8f1fd26640ccbf01dc63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-9904-2144
OpenAccessLink https://link.springer.com/10.1007/s00280-023-04504-z
PMID 36707434
PQID 2773996514
PQPubID 48447
PageCount 17
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9905199
proquest_miscellaneous_2849887887
proquest_miscellaneous_2770479045
proquest_journals_2773996514
pubmed_primary_36707434
crossref_citationtrail_10_1007_s00280_023_04504_z
crossref_primary_10_1007_s00280_023_04504_z
springer_journals_10_1007_s00280_023_04504_z
PublicationCentury 2000
PublicationDate 2023-02-01
PublicationDateYYYYMMDD 2023-02-01
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-01
  day: 01
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Cancer chemotherapy and pharmacology
PublicationTitleAbbrev Cancer Chemother Pharmacol
PublicationTitleAlternate Cancer Chemother Pharmacol
PublicationYear 2023
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Chrubasik-HausmannSVlachojannisJMcLachlanAJUnderstanding drug interactions with St John’s wort (Hypericum perforatum L.): impact of hyperforin contentJ Pharm Pharmacol2019711291381:CAS:528:DC%2BC1cXisVSnu74%3D10.1111/jphp.1285829411879
AoyamaTNishikawaKTakiguchiNTanabeKImanoMFukushimaRSakamotoJObaMSMoritaSKonoTTsuburayaADouble-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositisCancer Chemother Pharmacol201473104710541:CAS:528:DC%2BC2cXltFyitbY%3D10.1007/s00280-014-2440-x246526044000413
MatsudaCMunemotoYMishimaHNagataNOshiroMKataokaMSakamotoJAoyamaTMoritaSKonoTDouble-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositisCancer Chemother Pharmacol2015769710310.1007/s00280-015-2767-y259830224485889
YangJKjellssonMRostami-HodjeganATuckerGTThe effects of dose staggering on metabolic drug-drug interactionsEur J Pharm Sci2003202232321:CAS:528:DC%2BD3sXnvVOitL0%3D10.1016/s0928-0987(03)00200-814550889
NicolussiSDreweJButterweckVMeyer Zu SchwabedissenHEClinical relevance of St. John’s wort drug interactions revisitedBr J Pharmacol2020177121212261:CAS:528:DC%2BB3cXhtVKntrk%3D10.1111/bph.14936317426597056460
DürrDStiegerBKullak-UblickGARentschKMSteinertHCMeierPJFattingerKSt John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4Clin Pharmacol Ther20006859860410.1067/mcp.2000.11224011180019
VardyJDhillonHMClarkeSJOlesenILeslieFWarbyABeithJSullivanAHamiltonABealePRittauAMcLachlanAJInvestigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancerSpringerplus2013212610.1186/2193-1801-2-126235965623625417
EngelsFKde JongFASparreboomAMathotRALoosWJKitzenJJde BruijnPVerweijJMathijssenRHMedicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxelOncologist2007122913001:CAS:528:DC%2BD2sXlsVSqtbs%3D10.1634/theoncologist.12-3-29117405893
JacksonJPFreemanKMFrileyWWHermanAGBlackCBBrouwerKRRoeALPrediction of clinically relevant herb-drug clearance interactions using sandwich-cultured human hepatocytes: Schisandra sppCase Study Drug Metab Dispos201745101910261:CAS:528:DC%2BC2sXitVWqsrrE10.1124/dmd.117.07540828698304
PaineMFWidmerWWHartHLPusekSNBeaversKLCrissABBrownSSThomasBFWatkinsPBA furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interactionAm J Clin Nutr200683109711051:CAS:528:DC%2BD28XkvFOrsbs%3D10.1093/ajcn/83.5.109716685052
CohenMHunterJComplementary medicine products: interpreting the evidence baseIntern Med J20174799299810.1111/imj.1353428891185
ParvezMMBasitAJariwalaPBGáborikZKisEHeywardSRedinboMRPrasadBQuantitative investigation of irinotecan metabolism, transport, and gut microbiome activationDrug Metab Dispos2021496836931:CAS:528:DC%2BB3MXitV2ltLvJ10.1124/dmd.121.000476340747308407663
HartmannJTHaapMKoppHGLippHPTyrosine kinase inhibitors—a review on pharmacology, metabolism and side effectsCurr Drug Metab2009104704811:CAS:528:DC%2BD1MXhtVGhtbzN10.2174/13892000978889797519689244
MizunoNNiwaTYotsumotoYSugiyamaYImpact of drug transporter studies on drug discovery and developmentPharmacol Rev2003554254611:CAS:528:DC%2BD3sXnsVynuro%3D10.1124/pr.55.3.112869659
Bar-SelaGTsalicMFriedGGoldbergHWheat grass juice may improve hematological toxicity related to chemotherapy in breast cancer patients: a pilot studyNutr Cancer20075843481:CAS:528:DC%2BD2sXpsVKmur8%3D10.1080/0163558070130808317571966
BakerSDSparreboomAVerweijJJCpClinical pharmacokinetics of docetaxelClin Pharmacokinet2006452352521:CAS:528:DC%2BD28XjsFOksbw%3D10.2165/00003088-200645030-0000216509758
JiangSLLiuHJLiuZCLiuNLiuRKangYRJiJGZhangCHuaBJKangSJAdjuvant effects of fermented red ginseng extract on advanced non-small cell lung cancer patients treated with chemotherapyChin J Integr Med20172333133710.1007/s11655-015-2146-x26142337
NiuJStraubingerRMMagerDEPharmacodynamic drug-drug interactionsClin Pharmacol Ther20191051395140610.1002/cpt.143430912119
TobinPJBealePNoneyLLiddellSRivoryLPClarkeSA pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancerCancer Chemother Pharmacol2006573093161:CAS:528:DC%2BD28XislWkurk%3D10.1007/s00280-005-0053-016003560
ChengFLiQWangJZengFZhangYEffects and safety evaluation of Wuzhi capsules combined with tacrolimus for the treatment of kidney transplantation recipientsJ Clin Pharm Ther202146163616491:CAS:528:DC%2BB3MXisV2mtLjJ10.1111/jcpt.1349334342024
AdiwidjajaJMcLachlanAJBoddyAVCurcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactionsExpert Opin Drug Metab Toxicol2017139539721:CAS:528:DC%2BC2sXhtlSrtLrK10.1080/17425255.2017.136027928776444
SanejaAKhareVAlamNDubeyRDGuptaPNAdvances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevanceExpert Opin Drug Deliv2014111211381:CAS:528:DC%2BC3sXhvFOnu7%2FF10.1517/17425247.2014.86501424295039
ImanagaJKotegawaTImaiHTsutsumiKYoshizatoTOhyamaTShirasakaYTamaiITateishiTOhashiKThe effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humansPharmacogenet Genom20112184931:CAS:528:DC%2BC3MXjsV2jsw%3D%3D10.1097/fpc.0b013e32834300cc
KummarSCopurMSRoseMWadlerSStephensonJO’RourkeMBrenckmanWTiltonRLiuSHJiangZSuTChengYCChuEA phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancerClin Colorectal Cancer20111085961:CAS:528:DC%2BC3MXhtlKju7nI10.1016/j.clcc.2011.03.00321859559
MathijssenRHVerweijJde BruijnPLoosWJSparreboomAEffects of St. John’s wort on irinotecan metabolismJ Natl Cancer Inst200294124712491:CAS:528:DC%2BD38XntVyjsL8%3D10.1093/jnci/94.16.124712189228
RedversALaugharneRKanagaratnamGSrinivasanGJPBHow many patients self-medicate with St John’s wort?Psychiatr Bull20012525425610.1192/pb.25.7.254
HlubockyFJRatainMJWenMDaughertyCKComplementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision makingJ Clin Oncol20072554855410.1200/JCO.2005.03.980017290064
McDonaldMGTianDDThummelKEPaineMFRettieAEModulation of major human liver microsomal cytochromes P450 by Component alkaloids of goldenseal: time-dependent inhibition and allosteric effectsDrug Metab Dispos202048101810271:CAS:528:DC%2BB3cXitVamu7jF10.1124/dmd.120.091041325914167543482
GreenblattDJMechanisms and consequences of drug-drug interactionsClin Pharmacol Drug Dev201761181241:CAS:528:DC%2BC2sXjs12ntr0%3D10.1002/cpdd.33928263467
MathijssenRHvan AlphenRJVerweijJLoosWJNooterKStoterGSparreboomAClinical pharmacokinetics and metabolism of irinotecan (CPT-11)Clin Cancer Res20017218221941:CAS:528:DC%2BD3MXmsVOmsbg%3D11489791
RodriguesADLaiYShenHVarmaMVSRowlandAOswaldSInduction of human intestinal and hepatic organic anion transporting polypeptides: where is the evidence for its relevance in drug-drug interactions?Drug Metab Dispos2020482052161:CAS:528:DC%2BB3cXntlGms7c%3D10.1124/dmd.119.08961531879282
IchikiMWatayaHYamadaKTsurutaNTakeokaHOkayamaYSasakiJHoshinoTPreventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancerOnco Targets Ther2017105107511310.2147/ott.S145613291234095661491
HussaartsKHurkmansDPOomen-de HoopEvan HartenLJBerghuisSvan AlphenRJSpieringsLEAvan Rossum-SchornagelQCVastbinderMBvan SchaikRHNvan GelderTJagerAvan LeeuwenRWFMathijssenRHJImpact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifenCancers (Basel)201910.3390/cancers1103040330909366
MalkiMAPearsonERDrug-drug-gene interactions and adverse drug reactionsPharmacogenom J2020203553661:CAS:528:DC%2BC1MXit1yjsrnF10.1038/s41397-019-0122-0
YamashitaTArakiKTomifujiMKamideDTanakaYShiotaniAA traditional Japanese medicine–Hangeshashinto (TJ-14)–alleviates chemoradiation-induced mucositis and improves rates of treatment completionSupport Care Cancer201523293510.1007/s00520-014-2315-z24943276
ManskyPJWallerstedtDBSannesTSStaglJJohnsonLLBlackmanMRGremJLSwainSMMonahanBPNCCAM/NCI Phase 1 study of mistletoe extract and gemcitabine in patients with advanced solid tumorsEvid Based Complement Alternat Med2013201396459210.1155/2013/964592242859803826324
van ErpNPBakerSDZhaoMRudekMAGuchelaarHJNortierJWSparreboomAGelderblomHEffect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecanClin Cancer Res200511780078061:CAS:528:DC%2BD2MXhtF2isL7F10.1158/1078-0432.CCR-05-128816278402
WuYLZhouCHuCPFengJLuSHuangYLiWHouMShiJHLeeKYXuCRMasseyDKimMShiYGeaterSLAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol2014152132221:CAS:528:DC%2BC2cXhtF2gu78%3D10.1016/s1470-2045(13)70604-124439929
CohenEEWuKHartfordCKocherginskyMEatonKNZhaYNallariAMaitlandMLFox-KayKMoshierKHouseLRamirezJUndeviaSDFlemingGFGajewskiTFRatainMJPhase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patientsClin Cancer Res201218478547931:CAS:528:DC%2BC38Xht1ygsb%2FJ10.1158/1078-0432.Ccr-12-0110228725754410974
FahrmayrCKönigJAugeDMiethMFrommMFIdentification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cellsBr J Pharmacol2012165183618471:CAS:528:DC%2BC38XjsVKqu7o%3D10.1111/j.1476-5381.2011.01672.x219237553372834
LiRGuoWFuZDingGWangZFuHA study about drug combination therapy of Schisandra sphenanthera extract and Rapamycin in healthy subjectsCan J Physiol Pharmacol2012909419451:CAS:528:DC%2BC38XpvFCrsr4%3D10.1139/y2012-08022686837
ChanWJJ
B Oh (4504_CR3) 2010; 6
FJ Hlubocky (4504_CR4) 2007; 25
P Smith (4504_CR41) 2004; 24
DG Bailey (4504_CR46) 1998; 46
MM Parvez (4504_CR40) 2021; 49
LV Sequist (4504_CR78) 2013; 31
S Reif (4504_CR50) 2002; 58
J Imanaga (4504_CR32) 2011; 21
AK Goey (4504_CR92) 2013; 76
M Ichiki (4504_CR72) 2017; 10
A Saneja (4504_CR17) 2014; 11
F Cheng (4504_CR62) 2021; 46
A Giordano (4504_CR64) 2019
H Zhang (4504_CR29) 2018; 122
SK Mandal (4504_CR68) 2020; 160
HW Xin (4504_CR61) 2007; 64
RH Mathijssen (4504_CR38) 2002; 94
G Bar-Sela (4504_CR87) 2007; 58
PJ Mansky (4504_CR94) 2013; 2013
EE Cohen (4504_CR49) 2012; 18
NP van Erp (4504_CR88) 2011; 67
PJ Tobin (4504_CR95) 2006; 57
JH Lin (4504_CR16) 2003; 42
MG McDonald (4504_CR30) 2020; 48
NP van Erp (4504_CR97) 2005; 11
BK Vogler (4504_CR79) 1999; 55
TY Sun (4504_CR86) 2015; 23
S Nicolussi (4504_CR23) 2020; 177
EJ Cox (4504_CR28) 2021; 73
J Yang (4504_CR24) 2003; 20
S Tocaciu (4504_CR96) 2018; 17
X Zhuo (4504_CR53) 2004; 32
SN Sehgal (4504_CR52) 2003; 35
R Li (4504_CR58) 2012; 90
H Kappauf (4504_CR2) 2000; 8
OB Gbolahan (4504_CR89) 2022; 15
ML Veronese (4504_CR51) 2003; 43
C Fahrmayr (4504_CR55) 2012; 165
J Vardy (4504_CR98) 2013; 2
RF Frye (4504_CR42) 2004; 76
T Yamashita (4504_CR71) 2015; 23
J Barnes (4504_CR8) 2003; 55
JT Hartmann (4504_CR14) 2009; 10
S Kummar (4504_CR84) 2011; 10
S Chrubasik-Hausmann (4504_CR20) 2019; 71
WJJ Chan (4504_CR6) 2018; 14
MJ Dolton (4504_CR19) 2012; 92
MA Malki (4504_CR31) 2020; 20
WF Pirl (4504_CR35) 2004
T Aoyama (4504_CR75) 2014; 73
MF Paine (4504_CR25) 2006; 83
DJ Klein (4504_CR66) 2013; 23
RH Mathijssen (4504_CR39) 2001; 7
B Stieger (4504_CR18) 2017; 57
B Peng (4504_CR43) 2005; 44
JP Jackson (4504_CR57) 2017; 45
OQ Yin (4504_CR48) 2010; 50
SL Jiang (4504_CR82) 2017; 23
FK Engels (4504_CR91) 2007; 12
S Kimura (4504_CR47) 2011; 35
J Adiwidjaja (4504_CR65) 2017; 13
N Guha (4504_CR93) 2009; 118
C Matsuda (4504_CR74) 2015; 76
GDM Veerman (4504_CR99) 2022; 151
K Hussaarts (4504_CR67) 2019
NB Kumar (4504_CR5) 2002; 9
A Florence (4504_CR12) 1998
AD Rodrigues (4504_CR21) 2020; 48
S Huang (4504_CR56) 2021; 49
N Mizuno (4504_CR15) 2003; 55
E Fontana (4504_CR26) 2005; 6
PD Coxeter (4504_CR10) 2004; 11
D Dürr (4504_CR37) 2000; 68
K Nishikawa (4504_CR76) 2018; 9
AK Goey (4504_CR45) 2014; 53
F Carmona (4504_CR9) 2013; 23
GL Plosker (4504_CR59) 2000; 59
K Mori (4504_CR73) 2003; 51
M Cohen (4504_CR7) 2017; 47
J Niu (4504_CR11) 2019; 105
A Redvers (4504_CR36) 2001; 25
K Ahlberg (4504_CR80) 2003; 362
W Lam (4504_CR83) 2010; 2
SJ Brantley (4504_CR27) 2014; 42
J Li (4504_CR63) 2017; 45
EB Mougey (4504_CR33) 2011; 51
F Teng (4504_CR60) 2022; 43
YL Wu (4504_CR77) 2014; 15
CL Braal (4504_CR90) 2020
MLJC Slevin (4504_CR54) 1991; 67
C Ekhart (4504_CR13) 2009; 35
BJ Gurley (4504_CR69) 2005; 77
CA Changou (4504_CR85) 2021; 26
4504_CR1
SD Baker (4504_CR44) 2006; 45
MC Cox (4504_CR34) 2006; 12
DJ Greenblatt (4504_CR22) 2017; 6
BJ Gurley (4504_CR70) 2008; 83
DL Barton (4504_CR81) 2013; 105
References_xml – reference: BraalCLHussaartsKSeurenLOomen-de HoopEde BruijnPBuckSAJBosMThijs-VisserMFZuetenhorstHJMMathijssen-van SteinDVastbinderMBvan LeeuwenRWFvan GelderTKoolenSLWJagerAMathijssenRHJInfluence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifenBreast Cancer Res Treat202010.1007/s10549-020-05829-6328036368025281
– reference: SlevinMLJCThe clinical pharmacology of etoposideCancer1991673193291:STN:280:DyaK3M%2FosVOksg%3D%3D10.1002/1097-0142(19910101)67:1+<319::AID-CNCR2820671319>3.0.CO;2-D1984835
– reference: LamWBussomSGuanFJiangZZhangWGullenEALiuSHChengYCThe four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicitySci Transl Med2010245ra591:CAS:528:DC%2BC3cXhtFejs7jL10.1126/scitranslmed.300127020720216
– reference: SequistLVYangJCYamamotoNO'ByrneKHirshVMokTGeaterSLOrlovSTsaiCMBoyerMSuWCBennounaJKatoTGorbunovaVLeeKHShahRMasseyDZazulinaVShahidiMSchulerMPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331332733341:CAS:528:DC%2BC3sXhs1KrsrzP10.1200/jco.2012.44.280623816960
– reference: BartonDLLiuHDakhilSRLinquistBSloanJANicholsCRMcGinnTWStellaPJSeegerGRSoodALoprinziCLWisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2J Natl Cancer Inst20131051230123810.1093/jnci/djt181238530573888141
– reference: LiJChenSQinXFuQBiHZhangYWangXLiuLWangCHuangMWuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent for renal transplant recipients who are CYP3A5 expressers: a two-phase prospective studyDrug Metab Dispos201745111411191:CAS:528:DC%2BC1cXjtlehtro%3D10.1124/dmd.117.07673728864749
– reference: BaileyDGMalcolmJArnoldOSpenceDGrapefruit juice–drug interactionsBr J Clin Pharmacol1998461011101:CAS:528:DyaK1cXlsFCitrY%3D10.1046/j.1365-2125.1998.00764.x97238171873672
– reference: BarnesJQuality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and qualityBr J Clin Pharmacol20035522623310.1046/j.1365-2125.2003.01810.x126309711884210
– reference: TengFWangWZhangWQuJLiuBChenJLiuSLiMChenWWeiHEffect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteersBiopharm Drug Dispos2022431191291:CAS:528:DC%2BB38Xit1Gqsb%2FO10.1002/bdd.231235180322
– reference: GurleyBJGardnerSFHubbardMAWilliamsDKGentryWBKhanIAShahAIn vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypesClin Pharmacol Ther2005774154261:CAS:528:DC%2BD2MXktFCrtLY%3D10.1016/j.clpt.2005.01.00915900287
– reference: CohenMHunterJComplementary medicine products: interpreting the evidence baseIntern Med J20174799299810.1111/imj.1353428891185
– reference: FlorenceAAttwoodDPhysicochemical drug interactions and incompatibilitiesPhysicochemical principles of pharmacy1998New YorkSpringer44949210.1007/978-1-349-14416-7_11
– reference: ChengFLiQWangJZengFZhangYEffects and safety evaluation of Wuzhi capsules combined with tacrolimus for the treatment of kidney transplantation recipientsJ Clin Pharm Ther202146163616491:CAS:528:DC%2BB3MXisV2mtLjJ10.1111/jcpt.1349334342024
– reference: VardyJDhillonHMClarkeSJOlesenILeslieFWarbyABeithJSullivanAHamiltonABealePRittauAMcLachlanAJInvestigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancerSpringerplus2013212610.1186/2193-1801-2-126235965623625417
– reference: MalkiMAPearsonERDrug-drug-gene interactions and adverse drug reactionsPharmacogenom J2020203553661:CAS:528:DC%2BC1MXit1yjsrnF10.1038/s41397-019-0122-0
– reference: MathijssenRHVerweijJde BruijnPLoosWJSparreboomAEffects of St. John’s wort on irinotecan metabolismJ Natl Cancer Inst200294124712491:CAS:528:DC%2BD38XntVyjsL8%3D10.1093/jnci/94.16.124712189228
– reference: GuhaNKwanMLQuesenberryCPJrWeltzienEKCastilloALCaanBJSoy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the life after cancer epidemiology studyBreast Cancer Res Treat20091183954051:CAS:528:DC%2BD1MXht1Ons7%2FF10.1007/s10549-009-0321-5192218743470874
– reference: WuYLZhouCHuCPFengJLuSHuangYLiWHouMShiJHLeeKYXuCRMasseyDKimMShiYGeaterSLAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol2014152132221:CAS:528:DC%2BC2cXhtF2gu78%3D10.1016/s1470-2045(13)70604-124439929
– reference: CoxeterPDMcLachlanAJDukeCCRoufogalisBDHerb-drug interactions: an evidence based approachCurr Med Chem200411151315251:CAS:528:DC%2BD2cXktlOgtLo%3D10.2174/092986704336519815180581
– reference: NishikawaKAoyamaTObaMSYoshikawaTMatsudaCMunemotoYTakiguchiNTanabeKNagataNImanoMOshiroMFukushimaRKataokaMMoritaSTsuburayaAMishimaHKonoTSakamotoJThe clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C)J Cancer20189172517301:CAS:528:DC%2BC1MXht12hsbfL10.7150/jca.24733298056975968759
– reference: ManskyPJWallerstedtDBSannesTSStaglJJohnsonLLBlackmanMRGremJLSwainSMMonahanBPNCCAM/NCI Phase 1 study of mistletoe extract and gemcitabine in patients with advanced solid tumorsEvid Based Complement Alternat Med2013201396459210.1155/2013/964592242859803826324
– reference: YamashitaTArakiKTomifujiMKamideDTanakaYShiotaniAA traditional Japanese medicine–Hangeshashinto (TJ-14)–alleviates chemoradiation-induced mucositis and improves rates of treatment completionSupport Care Cancer201523293510.1007/s00520-014-2315-z24943276
– reference: YinOQGallagherNLiAZhouWHarrellRSchranHEffect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participantsJ Clin Pharmacol2010501881941:CAS:528:DC%2BC3cXks1Sksbg%3D10.1177/009127000933613719948946
– reference: HlubockyFJRatainMJWenMDaughertyCKComplementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision makingJ Clin Oncol20072554855410.1200/JCO.2005.03.980017290064
– reference: SmithPBullockJMBookerBMHaasCEBerensonCSJuskoWJThe influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylatePharmacotherapy200424150815141:CAS:528:DC%2BD2cXhtVWrsL%2FF10.1592/phco.24.16.1508.5095815537555
– reference: AhlbergKEkmanTGaston-JohanssonFMockVAssessment and management of cancer-related fatigue in adultsLancet200336264065010.1016/s0140-6736(03)14186-412944066
– reference: BakerSDSparreboomAVerweijJJCpClinical pharmacokinetics of docetaxelClin Pharmacokinet2006452352521:CAS:528:DC%2BD28XjsFOksbw%3D10.2165/00003088-200645030-0000216509758
– reference: MoriKKondoTKamiyamaYKanoYTominagaKPreventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancerCancer Chemother Pharmacol2003514034061:CAS:528:DC%2BD3sXjsVOqsrw%3D10.1007/s00280-003-0585-012687289
– reference: MathijssenRHvan AlphenRJVerweijJLoosWJNooterKStoterGSparreboomAClinical pharmacokinetics and metabolism of irinotecan (CPT-11)Clin Cancer Res20017218221941:CAS:528:DC%2BD3MXmsVOmsbg%3D11489791
– reference: DürrDStiegerBKullak-UblickGARentschKMSteinertHCMeierPJFattingerKSt John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4Clin Pharmacol Ther20006859860410.1067/mcp.2000.11224011180019
– reference: CoxMCLowJLeeJWalsheJDenduluriNBermanAPermenterMGPetrosWPPriceDKFiggWDSparreboomASwainSMInfluence of garlic (Allium sativum) on the pharmacokinetics of docetaxelClin Cancer Res200612463646401:CAS:528:DC%2BD28XnvVGks7g%3D10.1158/1078-0432.CCR-06-038816899612
– reference: ZhuoXZhengNFelixCABlairIAKinetics and regulation of cytochrome P450-mediated etoposide metabolismDrug Metab Dispos20043299310001:CAS:528:DC%2BD2cXnsVegtb8%3D15319341
– reference: AdiwidjajaJMcLachlanAJBoddyAVCurcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactionsExpert Opin Drug Metab Toxicol2017139539721:CAS:528:DC%2BC2sXhtlSrtLrK10.1080/17425255.2017.136027928776444
– reference: KummarSCopurMSRoseMWadlerSStephensonJO’RourkeMBrenckmanWTiltonRLiuSHJiangZSuTChengYCChuEA phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancerClin Colorectal Cancer20111085961:CAS:528:DC%2BC3MXhtlKju7nI10.1016/j.clcc.2011.03.00321859559
– reference: AoyamaTNishikawaKTakiguchiNTanabeKImanoMFukushimaRSakamotoJObaMSMoritaSKonoTTsuburayaADouble-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositisCancer Chemother Pharmacol201473104710541:CAS:528:DC%2BC2cXltFyitbY%3D10.1007/s00280-014-2440-x246526044000413
– reference: XinHWWuXCLiQYuARZhuMShenYSuDXiongLEffects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteersBr J Clin Pharmacol2007644694751:CAS:528:DC%2BD2sXht1Srt7rM10.1111/j.1365-2125.2007.02922.x175067802048562
– reference: MougeyEBLangJEWenXLimaJJEffect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukastJ Clin Pharmacol2011517517601:CAS:528:DC%2BC3MXntVCgsbo%3D10.1177/009127001037447220974993
– reference: BrantleySJArgikarAALinYSNagarSPaineMFHerb-drug interactions: challenges and opportunities for improved predictionsDrug Metab Dispos2014423013171:CAS:528:DC%2BC2cXlsVCgtL8%3D10.1124/dmd.113.055236243353903935140
– reference: ChanWJJMcLachlanAJWheateNJHarnettJEAn evaluation of garlic products available in Australian pharmacies–from the label to the laboratoryJ Herb Med201814616710.1016/j.hermed.2018.09.004
– reference: EngelsFKde JongFASparreboomAMathotRALoosWJKitzenJJde BruijnPVerweijJMathijssenRHMedicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxelOncologist2007122913001:CAS:528:DC%2BD2sXlsVSqtbs%3D10.1634/theoncologist.12-3-29117405893
– reference: CohenEEWuKHartfordCKocherginskyMEatonKNZhaYNallariAMaitlandMLFox-KayKMoshierKHouseLRamirezJUndeviaSDFlemingGFGajewskiTFRatainMJPhase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patientsClin Cancer Res201218478547931:CAS:528:DC%2BC38Xht1ygsb%2FJ10.1158/1078-0432.Ccr-12-0110228725754410974
– reference: VoglerBKPittlerMHErnstEThe efficacy of ginseng. A systematic review of randomised clinical trialsEur J Clin Pharmacol1999555675751:STN:280:DC%2BD3c%2FgvFChsA%3D%3D10.1007/s00228005067410541774
– reference: JacksonJPFreemanKMFrileyWWHermanAGBlackCBBrouwerKRRoeALPrediction of clinically relevant herb-drug clearance interactions using sandwich-cultured human hepatocytes: Schisandra sppCase Study Drug Metab Dispos201745101910261:CAS:528:DC%2BC2sXitVWqsrrE10.1124/dmd.117.07540828698304
– reference: GoeyAKMeijermanIRosingHBurgersJAMergui-RoelvinkMKeessenMMarchettiSBeijnenJHSchellensJHThe effect of Echinacea purpurea on the pharmacokinetics of docetaxelBr J Clin Pharmacol2013764674741:CAS:528:DC%2BC3sXhtlaitLjL10.1111/bcp.12159237011843769673
– reference: MizunoNNiwaTYotsumotoYSugiyamaYImpact of drug transporter studies on drug discovery and developmentPharmacol Rev2003554254611:CAS:528:DC%2BD3sXnsVynuro%3D10.1124/pr.55.3.112869659
– reference: VeroneseMLGillenLPBurkeJPDorvalEPHauckWWPequignotEWaldmanSAGreenbergHEExposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juiceJ Clin Pharmacol2003438318391:CAS:528:DC%2BD3sXmsFyqtb8%3D10.1177/009127000325605912953340
– reference: HussaartsKHurkmansDPOomen-de HoopEvan HartenLJBerghuisSvan AlphenRJSpieringsLEAvan Rossum-SchornagelQCVastbinderMBvan SchaikRHNvan GelderTJagerAvan LeeuwenRWFMathijssenRHJImpact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifenCancers (Basel)201910.3390/cancers1103040330909366
– reference: KumarNBHopkinsKAllenKRiccardiDBesterman-DahanKMoyersSJCCUse of complementary/integrative nutritional therapies during cancer treatment: implications in clinical practiceCancer Control2002923624310.1177/10732748020090030712060821
– reference: ImanagaJKotegawaTImaiHTsutsumiKYoshizatoTOhyamaTShirasakaYTamaiITateishiTOhashiKThe effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humansPharmacogenet Genom20112184931:CAS:528:DC%2BC3MXjsV2jsw%3D%3D10.1097/fpc.0b013e32834300cc
– reference: GiordanoATommonaroGCurcumin and cancerNutrients201910.3390/nu11102376319058857019547
– reference: KimuraSKakoSWadaHSakamotoKAshizawaMSatoMTerasakoKKikuchiMNakasoneHOkudaSYamazakiROshimaKNishidaJWatanabeTKandaYCan grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?Leuk Res201135e11e1210.1016/j.leukres.2010.09.01420952061
– reference: TobinPJBealePNoneyLLiddellSRivoryLPClarkeSA pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancerCancer Chemother Pharmacol2006573093161:CAS:528:DC%2BD28XislWkurk%3D10.1007/s00280-005-0053-016003560
– reference: National Center for Complementary and Integrative Health (2022) Complementary, alternative, or integrative health: What’s in a name? National Center for Complementary and Integrative Health. https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name. Accessed 14 Sep 2022
– reference: SunTYLiJSChenCEffects of blending wheatgrass juice on enhancing phenolic compounds and antioxidant activities of traditional kombucha beverageJ Food Drug Anal2015237097181:CAS:528:DC%2BC2MXlsFegsbw%3D10.1016/j.jfda.2015.01.009289114879345444
– reference: GreenblattDJMechanisms and consequences of drug-drug interactionsClin Pharmacol Drug Dev201761181241:CAS:528:DC%2BC2sXjs12ntr0%3D10.1002/cpdd.33928263467
– reference: EkhartCRodenhuisSSmitsPHBeijnenJHHuitemaADAn overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatmentCancer Treat Rev20093518311:CAS:528:DC%2BD1MXhtlSmur4%3D10.1016/j.ctrv.2008.07.00318771857
– reference: van ErpNPBakerSDZhaoMRudekMAGuchelaarHJNortierJWSparreboomAGelderblomHEffect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecanClin Cancer Res200511780078061:CAS:528:DC%2BD2MXhtF2isL7F10.1158/1078-0432.CCR-05-128816278402
– reference: CoxEJTianDDClarkeJDRettieAEUnadkatJDThummelKEMcCuneJSPaineMFModeling Pharmacokinetic natural product-drug interactions for decision-making: a NaPDI center recommended approachPharmacol Rev2021738478591:CAS:528:DC%2BB3MXhvFWgtbzF10.1124/pharmrev.120.000106337125177956993
– reference: Chrubasik-HausmannSVlachojannisJMcLachlanAJUnderstanding drug interactions with St John’s wort (Hypericum perforatum L.): impact of hyperforin contentJ Pharm Pharmacol2019711291381:CAS:528:DC%2BC1cXisVSnu74%3D10.1111/jphp.1285829411879
– reference: FontanaEDansettePMPoliSMCytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivityCurr Drug Metab200564134541:CAS:528:DC%2BD2MXhtVWku7rK10.2174/13892000577433063916248836
– reference: OhBButowPMullanBBealePPavlakisNRosenthalDClarkeSThe use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in AustraliaAsia Pac J Clin Oncol2010634234910.1111/j.1743-7563.2010.01329.x21114784
– reference: PengBLloydPSchranHClinical pharmacokinetics of imatinibClin Pharmacokinet2005448798941:CAS:528:DC%2BD2MXhtFSktbzF10.2165/00003088-200544090-0000116122278
– reference: van ErpNPBakerSDZandvlietASPloegerBAden HollanderMChenZden HartighJKönig-QuartelJMGuchelaarHJGelderblomHMarginal increase of sunitinib exposure by grapefruit juiceCancer Chemother Pharmacol20116769570310.1007/s00280-010-1367-020512335
– reference: PirlWFEvidence report on the occurrence, assessment, and treatment of depression in cancer patientsJ Natl Cancer Inst Monogr200410.1093/jncimonographs/lgh02615263039
– reference: RedversALaugharneRKanagaratnamGSrinivasanGJPBHow many patients self-medicate with St John’s wort?Psychiatr Bull20012525425610.1192/pb.25.7.254
– reference: MatsudaCMunemotoYMishimaHNagataNOshiroMKataokaMSakamotoJAoyamaTMoritaSKonoTDouble-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositisCancer Chemother Pharmacol2015769710310.1007/s00280-015-2767-y259830224485889
– reference: ReifSNicolsonMCBissetDReidMKloftCJaehdeUMcLeodHLEffect of grapefruit juice intake on etoposide bioavailabilityEur J Clin Pharmacol2002584914941:CAS:528:DC%2BD38XnvFOhtb4%3D10.1007/s00228-002-0495-912389073
– reference: PloskerGLFosterRHJDTacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantationTacrolimus2000593233891:CAS:528:DC%2BD3cXit1Smu74%3D
– reference: FryeRFFitzgeraldSMLagattutaTFHruskaMWEgorinMJEffect of St John’s wort on imatinib mesylate pharmacokineticsClin Pharmacol Ther2004763233291:CAS:528:DC%2BD2cXotlCmtLg%3D10.1016/j.clpt.2004.06.00715470331
– reference: IchikiMWatayaHYamadaKTsurutaNTakeokaHOkayamaYSasakiJHoshinoTPreventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancerOnco Targets Ther2017105107511310.2147/ott.S145613291234095661491
– reference: FahrmayrCKönigJAugeDMiethMFrommMFIdentification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cellsBr J Pharmacol2012165183618471:CAS:528:DC%2BC38XjsVKqu7o%3D10.1111/j.1476-5381.2011.01672.x219237553372834
– reference: KappaufHLeykauf-AmmonDBruntschUHorneberMKaiserGBüschelGGallmeierWMUse of and attitudes held towards unconventional medicine by patients in a department of internal medicine/oncology and haematologySupport Care Cancer200083143221:STN:280:DC%2BD3M%2FlvVequg%3D%3D10.1007/s00520990011110923773
– reference: GurleyBJSwainAHubbardMAHartsfieldFThadenJWilliamsDKGentryWBTongYSupplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivoClin Pharmacol Ther20088361691:CAS:528:DC%2BD2sXhsVylt7fI10.1038/sj.clpt.610022217495878
– reference: LinJHYamazakiMJCpRole of P-glycoprotein in pharmacokineticsClin Pharmacokinet20034259981:CAS:528:DC%2BD3sXptVymuw%3D%3D10.2165/00003088-200342010-0000312489979
– reference: ZhangHBuFLiLJiaoZMaGCaiWZhuangXLinHSShinJGXiangXPrediction of drug-drug interaction between tacrolimus and principal ingredients of Wuzhi Capsule in Chinese healthy volunteers using physiologically-based pharmacokinetic modellingBasic Clin Pharmacol Toxicol20181223313401:CAS:528:DC%2BC2sXhslSkur%2FN10.1111/bcpt.1291428945011
– reference: KleinDJThornCFDestaZFlockhartDAAltmanRBKleinTEPharmGKB summary: tamoxifen pathway, pharmacokineticsPharmacogenet Genom2013236436471:CAS:528:DC%2BC3sXhsFyktrnK10.1097/FPC.0b013e3283656bc1
– reference: VeermanGDMvan der WerffSCKoolenSLWMiedemaJROomen-de HoopEvan der MarkSCChandoesingPPde BruijnPWijsenbeekMSMathijssenRHJThe influence of green tea extract on nintedanib’s bioavailability in patients with pulmonary fibrosisBiomed Pharmacother20221511131011:CAS:528:DC%2BB38XitVCnu7zL10.1016/j.biopha.2022.11310135594703
– reference: StiegerBMahdiZMJägerWIntestinal and hepatocellular transporters: therapeutic effects and drug interactions of herbal supplementsAnnu Rev Pharmacol Toxicol2017573994161:CAS:528:DC%2BC28XhsFemtrzI10.1146/annurev-pharmtox-010716-10501027648763
– reference: SehgalSNSirolimus: its discovery, biological properties, and mechanism of actionTransplant Proc2003357s14s1:CAS:528:DC%2BD3sXksFGqt78%3D10.1016/s0041-1345(03)00211-212742462
– reference: LiRGuoWFuZDingGWangZFuHA study about drug combination therapy of Schisandra sphenanthera extract and Rapamycin in healthy subjectsCan J Physiol Pharmacol2012909419451:CAS:528:DC%2BC38XpvFCrsr4%3D10.1139/y2012-08022686837
– reference: HartmannJTHaapMKoppHGLippHPTyrosine kinase inhibitors—a review on pharmacology, metabolism and side effectsCurr Drug Metab2009104704811:CAS:528:DC%2BD1MXhtVGhtbzN10.2174/13892000978889797519689244
– reference: McDonaldMGTianDDThummelKEPaineMFRettieAEModulation of major human liver microsomal cytochromes P450 by Component alkaloids of goldenseal: time-dependent inhibition and allosteric effectsDrug Metab Dispos202048101810271:CAS:528:DC%2BB3cXitVamu7jF10.1124/dmd.120.091041325914167543482
– reference: GoeyAKMeijermanIRosingHMarchettiSMergui-RoelvinkMKeessenMBurgersJABeijnenJHSchellensJHThe effect of St John’s wort on the pharmacokinetics of docetaxelClin Pharmacokinet2014531031101:CAS:528:DC%2BC2cXksVaksQ%3D%3D10.1007/s40262-013-0102-524068654
– reference: DoltonMJRoufogalisBDMcLachlanAJFruit juices as perpetrators of drug interactions: the role of organic anion-transporting polypeptidesClin Pharmacol Ther2012926226301:CAS:528:DC%2BC38XhsFChsbnN10.1038/clpt.2012.15923033114
– reference: ChangouCAShiahHSChenLTLiuSLuhFLiuSHChengYCYenYA Phase II clinical trial on the combination therapy of PHY906 plus capecitabine in hepatocellular carcinomaOncologist202126e367e3731:CAS:528:DC%2BB38XhtVeksLfM10.1002/onco.1358233140457
– reference: NicolussiSDreweJButterweckVMeyer Zu SchwabedissenHEClinical relevance of St. John’s wort drug interactions revisitedBr J Pharmacol2020177121212261:CAS:528:DC%2BB3cXhtVKntrk%3D10.1111/bph.14936317426597056460
– reference: GbolahanOBO’NeilBHMcReeAJSanoffHKFallonJKSmithPCIvanovaAMooreDTDumondJAsherGNA phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumorsClin Transl Sci202215130413151:CAS:528:DC%2BB38XhtFekur3I10.1111/cts.13250351577839099132
– reference: CarmonaFPereiraAMSHerbal medicines: old and new concepts, truths and misunderstandingsRev Bras Farmacogn20132337938510.1590/S0102-695X2013005000018
– reference: ParvezMMBasitAJariwalaPBGáborikZKisEHeywardSRedinboMRPrasadBQuantitative investigation of irinotecan metabolism, transport, and gut microbiome activationDrug Metab Dispos2021496836931:CAS:528:DC%2BB3MXitV2ltLvJ10.1124/dmd.121.000476340747308407663
– reference: NiuJStraubingerRMMagerDEPharmacodynamic drug-drug interactionsClin Pharmacol Ther20191051395140610.1002/cpt.143430912119
– reference: SanejaAKhareVAlamNDubeyRDGuptaPNAdvances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevanceExpert Opin Drug Deliv2014111211381:CAS:528:DC%2BC3sXhvFOnu7%2FF10.1517/17425247.2014.86501424295039
– reference: MandalSKMajiAKMishraSKIshfaqPMDevkotaHPSilvaASDasNGoldenseal (Hydrastis canadensis L.) and its active constituents: a critical review of their efficacy and toxicological issuesPharmacol Res20201601050851:CAS:528:DC%2BB3cXhsVyms73O10.1016/j.phrs.2020.10508532683037
– reference: RodriguesADLaiYShenHVarmaMVSRowlandAOswaldSInduction of human intestinal and hepatic organic anion transporting polypeptides: where is the evidence for its relevance in drug-drug interactions?Drug Metab Dispos2020482052161:CAS:528:DC%2BB3cXntlGms7c%3D10.1124/dmd.119.08961531879282
– reference: Bar-SelaGTsalicMFriedGGoldbergHWheat grass juice may improve hematological toxicity related to chemotherapy in breast cancer patients: a pilot studyNutr Cancer20075843481:CAS:528:DC%2BD2sXpsVKmur8%3D10.1080/0163558070130808317571966
– reference: TocaciuSOliverLJLowenthalRMPetersonGMPatelRShastriMMcGuinnessGOlesenIFittonJHThe effect of undaria pinnatifida fucoidan on the pharmacokinetics of letrozole and tamoxifen in patients with breast cancerIntegr Cancer Ther201817991051:CAS:528:DC%2BC1cXivVantr0%3D10.1177/153473541668401428008779
– reference: JiangSLLiuHJLiuZCLiuNLiuRKangYRJiJGZhangCHuaBJKangSJAdjuvant effects of fermented red ginseng extract on advanced non-small cell lung cancer patients treated with chemotherapyChin J Integr Med20172333133710.1007/s11655-015-2146-x26142337
– reference: YangJKjellssonMRostami-HodjeganATuckerGTThe effects of dose staggering on metabolic drug-drug interactionsEur J Pharm Sci2003202232321:CAS:528:DC%2BD3sXnvVOitL0%3D10.1016/s0928-0987(03)00200-814550889
– reference: HuangSZhangDLiYFanHLiuYHuangWDengCWangWSongXSchisandra sphenanthera: a comprehensive review of its botany, phytochemistry, pharmacology, and clinical applicationsAm J Chin Med202149157716221:CAS:528:DC%2BB38XmtlSitg%3D%3D10.1142/s0192415x2150074934559620
– reference: PaineMFWidmerWWHartHLPusekSNBeaversKLCrissABBrownSSThomasBFWatkinsPBA furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interactionAm J Clin Nutr200683109711051:CAS:528:DC%2BD28XkvFOrsbs%3D10.1093/ajcn/83.5.109716685052
– volume: 11
  start-page: 121
  year: 2014
  ident: 4504_CR17
  publication-title: Expert Opin Drug Deliv
  doi: 10.1517/17425247.2014.865014
– volume: 10
  start-page: 5107
  year: 2017
  ident: 4504_CR72
  publication-title: Onco Targets Ther
  doi: 10.2147/ott.S145613
– volume: 9
  start-page: 236
  year: 2002
  ident: 4504_CR5
  publication-title: Cancer Control
  doi: 10.1177/107327480200900307
– year: 2019
  ident: 4504_CR67
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11030403
– volume: 6
  start-page: 118
  year: 2017
  ident: 4504_CR22
  publication-title: Clin Pharmacol Drug Dev
  doi: 10.1002/cpdd.339
– volume: 25
  start-page: 254
  year: 2001
  ident: 4504_CR36
  publication-title: Psychiatr Bull
  doi: 10.1192/pb.25.7.254
– volume: 71
  start-page: 129
  year: 2019
  ident: 4504_CR20
  publication-title: J Pharm Pharmacol
  doi: 10.1111/jphp.12858
– volume: 49
  start-page: 683
  year: 2021
  ident: 4504_CR40
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.121.000476
– volume: 23
  start-page: 379
  year: 2013
  ident: 4504_CR9
  publication-title: Rev Bras Farmacogn
  doi: 10.1590/S0102-695X2013005000018
– volume: 64
  start-page: 469
  year: 2007
  ident: 4504_CR61
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.2007.02922.x
– volume: 105
  start-page: 1395
  year: 2019
  ident: 4504_CR11
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.1434
– volume: 13
  start-page: 953
  year: 2017
  ident: 4504_CR65
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1080/17425255.2017.1360279
– volume: 10
  start-page: 470
  year: 2009
  ident: 4504_CR14
  publication-title: Curr Drug Metab
  doi: 10.2174/138920009788897975
– volume: 51
  start-page: 403
  year: 2003
  ident: 4504_CR73
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-003-0585-0
– volume: 362
  start-page: 640
  year: 2003
  ident: 4504_CR80
  publication-title: Lancet
  doi: 10.1016/s0140-6736(03)14186-4
– volume: 76
  start-page: 323
  year: 2004
  ident: 4504_CR42
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2004.06.007
– volume: 35
  start-page: 7s
  year: 2003
  ident: 4504_CR52
  publication-title: Transplant Proc
  doi: 10.1016/s0041-1345(03)00211-2
– volume: 32
  start-page: 993
  year: 2004
  ident: 4504_CR53
  publication-title: Drug Metab Dispos
– volume: 55
  start-page: 567
  year: 1999
  ident: 4504_CR79
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050674
– volume: 23
  start-page: 331
  year: 2017
  ident: 4504_CR82
  publication-title: Chin J Integr Med
  doi: 10.1007/s11655-015-2146-x
– volume: 6
  start-page: 413
  year: 2005
  ident: 4504_CR26
  publication-title: Curr Drug Metab
  doi: 10.2174/138920005774330639
– volume: 73
  start-page: 1047
  year: 2014
  ident: 4504_CR75
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-014-2440-x
– volume: 51
  start-page: 751
  year: 2011
  ident: 4504_CR33
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270010374472
– volume: 118
  start-page: 395
  year: 2009
  ident: 4504_CR93
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-009-0321-5
– volume: 31
  start-page: 3327
  year: 2013
  ident: 4504_CR78
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2012.44.2806
– volume: 11
  start-page: 1513
  year: 2004
  ident: 4504_CR10
  publication-title: Curr Med Chem
  doi: 10.2174/0929867043365198
– start-page: 449
  volume-title: Physicochemical principles of pharmacy
  year: 1998
  ident: 4504_CR12
  doi: 10.1007/978-1-349-14416-7_11
– volume: 165
  start-page: 1836
  year: 2012
  ident: 4504_CR55
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.2011.01672.x
– volume: 10
  start-page: 85
  year: 2011
  ident: 4504_CR84
  publication-title: Clin Colorectal Cancer
  doi: 10.1016/j.clcc.2011.03.003
– volume: 20
  start-page: 355
  year: 2020
  ident: 4504_CR31
  publication-title: Pharmacogenom J
  doi: 10.1038/s41397-019-0122-0
– volume: 76
  start-page: 467
  year: 2013
  ident: 4504_CR92
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.12159
– volume: 26
  start-page: e367
  year: 2021
  ident: 4504_CR85
  publication-title: Oncologist
  doi: 10.1002/onco.13582
– volume: 151
  start-page: 113101
  year: 2022
  ident: 4504_CR99
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2022.113101
– volume: 2
  start-page: 45ra59
  year: 2010
  ident: 4504_CR83
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3001270
– volume: 35
  start-page: 18
  year: 2009
  ident: 4504_CR13
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2008.07.003
– volume: 177
  start-page: 1212
  year: 2020
  ident: 4504_CR23
  publication-title: Br J Pharmacol
  doi: 10.1111/bph.14936
– year: 2019
  ident: 4504_CR64
  publication-title: Nutrients
  doi: 10.3390/nu11102376
– volume: 25
  start-page: 548
  year: 2007
  ident: 4504_CR4
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.03.9800
– volume: 57
  start-page: 399
  year: 2017
  ident: 4504_CR18
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev-pharmtox-010716-105010
– volume: 42
  start-page: 59
  year: 2003
  ident: 4504_CR16
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200342010-00003
– volume: 20
  start-page: 223
  year: 2003
  ident: 4504_CR24
  publication-title: Eur J Pharm Sci
  doi: 10.1016/s0928-0987(03)00200-8
– volume: 42
  start-page: 301
  year: 2014
  ident: 4504_CR27
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.113.055236
– volume: 45
  start-page: 1019
  year: 2017
  ident: 4504_CR57
  publication-title: Case Study Drug Metab Dispos
  doi: 10.1124/dmd.117.075408
– volume: 76
  start-page: 97
  year: 2015
  ident: 4504_CR74
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-015-2767-y
– volume: 68
  start-page: 598
  year: 2000
  ident: 4504_CR37
  publication-title: Clin Pharmacol Ther
  doi: 10.1067/mcp.2000.112240
– volume: 83
  start-page: 1097
  year: 2006
  ident: 4504_CR25
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/83.5.1097
– volume: 23
  start-page: 709
  year: 2015
  ident: 4504_CR86
  publication-title: J Food Drug Anal
  doi: 10.1016/j.jfda.2015.01.009
– volume: 12
  start-page: 4636
  year: 2006
  ident: 4504_CR34
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-0388
– volume: 67
  start-page: 319
  year: 1991
  ident: 4504_CR54
  publication-title: Cancer
  doi: 10.1002/1097-0142(19910101)67:1+<319::AID-CNCR2820671319>3.0.CO;2-D
– volume: 46
  start-page: 1636
  year: 2021
  ident: 4504_CR62
  publication-title: J Clin Pharm Ther
  doi: 10.1111/jcpt.13493
– volume: 14
  start-page: 61
  year: 2018
  ident: 4504_CR6
  publication-title: J Herb Med
  doi: 10.1016/j.hermed.2018.09.004
– volume: 6
  start-page: 342
  year: 2010
  ident: 4504_CR3
  publication-title: Asia Pac J Clin Oncol
  doi: 10.1111/j.1743-7563.2010.01329.x
– volume: 7
  start-page: 2182
  year: 2001
  ident: 4504_CR39
  publication-title: Clin Cancer Res
– volume: 11
  start-page: 7800
  year: 2005
  ident: 4504_CR97
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-1288
– volume: 46
  start-page: 101
  year: 1998
  ident: 4504_CR46
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.1998.00764.x
– volume: 12
  start-page: 291
  year: 2007
  ident: 4504_CR91
  publication-title: Oncologist
  doi: 10.1634/theoncologist.12-3-291
– volume: 50
  start-page: 188
  year: 2010
  ident: 4504_CR48
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270009336137
– volume: 53
  start-page: 103
  year: 2014
  ident: 4504_CR45
  publication-title: Clin Pharmacokinet
  doi: 10.1007/s40262-013-0102-5
– volume: 122
  start-page: 331
  year: 2018
  ident: 4504_CR29
  publication-title: Basic Clin Pharmacol Toxicol
  doi: 10.1111/bcpt.12914
– volume: 23
  start-page: 643
  year: 2013
  ident: 4504_CR66
  publication-title: Pharmacogenet Genom
  doi: 10.1097/FPC.0b013e3283656bc1
– volume: 58
  start-page: 43
  year: 2007
  ident: 4504_CR87
  publication-title: Nutr Cancer
  doi: 10.1080/01635580701308083
– volume: 8
  start-page: 314
  year: 2000
  ident: 4504_CR2
  publication-title: Support Care Cancer
  doi: 10.1007/s005209900111
– volume: 77
  start-page: 415
  year: 2005
  ident: 4504_CR69
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2005.01.009
– volume: 47
  start-page: 992
  year: 2017
  ident: 4504_CR7
  publication-title: Intern Med J
  doi: 10.1111/imj.13534
– volume: 43
  start-page: 119
  year: 2022
  ident: 4504_CR60
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/bdd.2312
– volume: 35
  start-page: e11
  year: 2011
  ident: 4504_CR47
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2010.09.014
– volume: 67
  start-page: 695
  year: 2011
  ident: 4504_CR88
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-010-1367-0
– volume: 83
  start-page: 61
  year: 2008
  ident: 4504_CR70
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100222
– volume: 49
  start-page: 1577
  year: 2021
  ident: 4504_CR56
  publication-title: Am J Chin Med
  doi: 10.1142/s0192415x21500749
– volume: 73
  start-page: 847
  year: 2021
  ident: 4504_CR28
  publication-title: Pharmacol Rev
  doi: 10.1124/pharmrev.120.000106
– volume: 21
  start-page: 84
  year: 2011
  ident: 4504_CR32
  publication-title: Pharmacogenet Genom
  doi: 10.1097/fpc.0b013e32834300cc
– volume: 59
  start-page: 323
  year: 2000
  ident: 4504_CR59
  publication-title: Tacrolimus
– volume: 48
  start-page: 1018
  year: 2020
  ident: 4504_CR30
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.120.091041
– volume: 94
  start-page: 1247
  year: 2002
  ident: 4504_CR38
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/94.16.1247
– volume: 90
  start-page: 941
  year: 2012
  ident: 4504_CR58
  publication-title: Can J Physiol Pharmacol
  doi: 10.1139/y2012-080
– volume: 43
  start-page: 831
  year: 2003
  ident: 4504_CR51
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270003256059
– volume: 23
  start-page: 29
  year: 2015
  ident: 4504_CR71
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-014-2315-z
– volume: 57
  start-page: 309
  year: 2006
  ident: 4504_CR95
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-005-0053-0
– volume: 24
  start-page: 1508
  year: 2004
  ident: 4504_CR41
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.24.16.1508.50958
– volume: 48
  start-page: 205
  year: 2020
  ident: 4504_CR21
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.119.089615
– volume: 58
  start-page: 491
  year: 2002
  ident: 4504_CR50
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-002-0495-9
– year: 2004
  ident: 4504_CR35
  publication-title: J Natl Cancer Inst Monogr
  doi: 10.1093/jncimonographs/lgh026
– year: 2020
  ident: 4504_CR90
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-020-05829-6
– volume: 92
  start-page: 622
  year: 2012
  ident: 4504_CR19
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2012.159
– ident: 4504_CR1
– volume: 15
  start-page: 1304
  year: 2022
  ident: 4504_CR89
  publication-title: Clin Transl Sci
  doi: 10.1111/cts.13250
– volume: 18
  start-page: 4785
  year: 2012
  ident: 4504_CR49
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-12-0110
– volume: 15
  start-page: 213
  year: 2014
  ident: 4504_CR77
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(13)70604-1
– volume: 45
  start-page: 1114
  year: 2017
  ident: 4504_CR63
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.117.076737
– volume: 160
  start-page: 105085
  year: 2020
  ident: 4504_CR68
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2020.105085
– volume: 105
  start-page: 1230
  year: 2013
  ident: 4504_CR81
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djt181
– volume: 2
  start-page: 126
  year: 2013
  ident: 4504_CR98
  publication-title: Springerplus
  doi: 10.1186/2193-1801-2-126
– volume: 45
  start-page: 235
  year: 2006
  ident: 4504_CR44
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200645030-00002
– volume: 44
  start-page: 879
  year: 2005
  ident: 4504_CR43
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200544090-00001
– volume: 55
  start-page: 226
  year: 2003
  ident: 4504_CR8
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.2003.01810.x
– volume: 2013
  start-page: 964592
  year: 2013
  ident: 4504_CR94
  publication-title: Evid Based Complement Alternat Med
  doi: 10.1155/2013/964592
– volume: 55
  start-page: 425
  year: 2003
  ident: 4504_CR15
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.55.3.1
– volume: 17
  start-page: 99
  year: 2018
  ident: 4504_CR96
  publication-title: Integr Cancer Ther
  doi: 10.1177/1534735416684014
– volume: 9
  start-page: 1725
  year: 2018
  ident: 4504_CR76
  publication-title: J Cancer
  doi: 10.7150/jca.24733
SSID ssj0004133
Score 2.5417686
SecondaryResourceType review_article
Snippet Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food supplements are widely used by people...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 103
SubjectTerms Biological Products
Cancer
Cancer Research
Cancer therapies
Clinical outcomes
Clinical Relevance
Curcuma longa
Diarrhea
Dietary Supplements
Drug-Related Side Effects and Adverse Reactions
grapefruits
Herb-Drug Interactions
Humans
Hydrastis canadensis
Hypericum perforatum
Immune response
Medicine
Medicine & Public Health
Mucositis
Natural products
Neoplasms
Oncology
Pharmacodynamics
Pharmacokinetics
Pharmacology/Toxicology
Quality of Life
Review
Review Article
Schisandra
Side effects
SummonAdditionalLinks – databaseName: Springer Online Journals
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1RT9UwFD5BMMYXQRSdgqmJ4cXbZN26dvXNEAkPQG4UCW_L1rXhEu4gdxcT-PWedt1urgiJJnvrWdd2p-23nfN9BfikTcyMqmpa6go_UFiZUiVsTCsljIwzbZmPnp8eyuPj_OxMjQMprO2z3fuQpF-pB7KbjwJS3GMowpCY07snsIbbXe6m4_cfpws2JOsOkE85p5mMeaDK_L2O5e3oHsa8nyr5R7zUb0P76__XgQ14EWAn-dr5yUtYMc0mPDsKgfVN2B13Eta3I3KyYGS1I7JLxgtx69tXcOF_IXZsiJaELC_i5UGx_utOP7YlZVMT7RxqRoZU9vYLcYy12aVjVpGpcZzjSTsNxoGhSSZT_0WAt76Gn_vfTvYOaDivgWpElXNaJwpXy0SYPNeqzqRNZY4QoGS84iLTpTCixp4bYdEwt8yireCx1pWNWa1FugWrzVVj3gKpUikzmyBYSmpuK1PaLDNMKKtsjStiGQHrX1uhg5i5O1PjshhkmP1oFzjahR_t4i6Cz8M9152Ux6PW2703FGFat0UiJQI6gSAzgo9DMU5IF2UpG3N1422cbD9W84hNzhWu7nhF8KZzsKFJTlEPYR0-QS653mDgBMGXS5rJuRcGV05sTakIRr0DLpr-cE_f_Zv5e3ieeB92KT3bsDqf3ZgdeKp_zSft7IOfir8B14wyag
  priority: 102
  providerName: Springer Nature
Title Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance
URI https://link.springer.com/article/10.1007/s00280-023-04504-z
https://www.ncbi.nlm.nih.gov/pubmed/36707434
https://www.proquest.com/docview/2773996514
https://www.proquest.com/docview/2770479045
https://www.proquest.com/docview/2849887887
https://pubmed.ncbi.nlm.nih.gov/PMC9905199
Volume 91
WOSCitedRecordID wos000920951000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1432-0843
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0004133
  issn: 0344-5704
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED_Wdoy9rFv35bULGoy-LKK2I0vWXsZaWvawhdB1JW_GliWW0ThZnA7av34nWbFJy_IyMAHjs2Nxn9bd_Q7gvdJhpGVR0lwV-IES5QMquQlpIbkWYaJM5LLnl1_FcJiOx3LkN9xqX1a5sonOUJczZffIj2Ih0Jdy9O-f5r-pnRpls6t-hMYW7ERxyKxipiddiQca6GY8MmM0ESHzTTOudc7lFCl6LIpBTcjo7bpjuhdt3i-avJM5dQ7pbPd_l_IUnvhQlHxuZOcZPNDVHjz65pPte3A4amCtb_rkouvSqvvkkIw6wOub5_DLbSs2HRI18ZVfxEGG4vPnDaZsTfKqJMoK2YK05e31R2K72BZXttuKTLXtQ57UU0_suzbJZOq-EvDWF_Dj7PTi5Av1MxyowkhzSctYogWNuU5TJctEmIFIMSzII1Ywnqica14iAzQ3SJiayCAtZ6FShQmjUvHBS9iuZpV-DaQYCJGYGAOouGSm0LlJEh1xaaQp0UrmAUQrBmbKA5zbORtXWQvN7JieIdMzx_TsNoAP7T3zBt5jI_XBiqGZV_U667gZwLv2MiqpzbzklZ5dOxoL5Y-P2UCTMokWH48AXjWi1r6SRdnDUA__QawJYUtgQcLXr1STnw4sXFoANikD6K_EtXv1f6_0zeaV7sPj2KmOLes5gO3l4lq_hYfqz3JSL3qwJcbC_aY9p5A92Dk-HY7O8ez8--Vfl-1AEw
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgoALj_IyFFgk6KVZ4eeuFwkhBFStmkY5BJSbsde7IqhxQpyC0h_Fb2R2_VKoyK0HpNw83vgxr_XM9w3AS6lcT4ksp6nMcIPipQEVTLs0E0xxN5Las9XzL30-GMTjsRhuwe8GC2PaKhufaB11PpPmG_lrn3OMpQzj-7v5D2qmRpnqajNCo1KLY7X6hVu28u3RR3y_r3z_4NPowyGtpwpQibnPkua-QJv2mYpjKfKI64DHGKhSL8xCFsmUKZZjnqOYRsFYexplWehKmWnXyyULcN0rcBX9ODctZHzMOxymV42uD8KQRtwNa5COherZGibFCElxcTek5-uB8EJ2e7FJ869KrQ2AB7f_t0d3B27VqTZ5X9nGXdhSxQ5cP6mbCXZgb1jRdq96ZNSh0Moe2SPDjtB7dQ--28-mFQKkJHVnG7GUqLj-vOLMLUla5EQaI1qQtn2_fEMMSm9xatBkZKoMznpSTmvhGpVKJlO7C8JT78PnS3kkD2C7mBXqEZAs4DzSPiaIfh7qTKU6ipTHhBY6xyiQOuA1CpPImsDdzBE5TVrqaatkCSpZYpUsOXdgvz1nXtGXbJTebRQoqV1ZmXTa48CL9jA6IVNZSgs1O7MyZlQBLrNBJg4FRjT8OfCwUu32kgyLIKay-A98TelbAUOCvn6kmHyzZOjCEMwJ4UCvMY_u0v99p4833-lzuHE4Oukn_aPB8RO46VuzNS1Mu7C9XJypp3BN_lxOysUz6wAIfL1ss_kD4YeZpg
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgiouPMqjhgKLBL2QVf3c9SIhhCgRVUuUQ0G5ufZ6V6RqnBCnoPSn8euYXb8UKnLrASk3jzd-zGs9830D8Eoq11Miy2kqM9ygeGlABdMuzQRT3I2k9mz1_NsxHwzi0UgMN-B3g4UxbZWNT7SOOp9K84183-ccYynD-L6v67aI4UH__ewHNROkTKW1GadRqciRWv7C7Vv57vAA3_Vr3-9_Ovn4mdYTBqjEPGhBc1-gfftMxbEUecR1wGMMWqkXZiGLZMoUyzHnUUyjYKw9jbIsdKXMtOvlkgW47g24yYOAm7ERfMQ7TKZXjbEPwpBG3A1rwI6F7dl6JsVoSXFxN6SXq0HxSqZ7tWHzr6qtDYb9u__zY7wHd-oUnHyobOY-bKhiG7a-1E0G27A3rOi8lz1y0qHTyh7ZI8OO6Hv5AM7s59QKGVKSuuONWKpUXH9WcemWJC1yIo1xzUnb1l--JQa9Nz83KDMyUQZ_PS4ntXCNViXjid0d4akP4eu1PJJHsFlMC7UDJAs4j7SPiaOfhzpTqY4i5TGhhc4xOqQOeI3yJLImdjfzRc6TlpLaKlyCCpdYhUsuHXjTnjOraE3WSu82ypTULq5MOk1y4GV7GJ2TqTilhZpeWBkzwgCXWSMThwIjHf4ceFypeXtJhl0QU1z8B75iAK2AIUdfPVKMv1uSdGGI54RwoNeYSnfp_77TJ-vv9AVsobUkx4eDo6dw27cWbDqbdmFzMb9Qz-CW_LkYl_Pn1hcQOL1uq_kDtiGiWg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interactions+between+natural+products+and+cancer+treatments%3A+underlying+mechanisms+and+clinical+importance&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Chan%2C+Wai-Jo+Jocelin&rft.au=Adiwidjaja%2C+Jeffry&rft.au=McLachlan%2C+Andrew+J.&rft.au=Boddy%2C+Alan+V.&rft.date=2023-02-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0344-5704&rft.eissn=1432-0843&rft.volume=91&rft.issue=2&rft.spage=103&rft.epage=119&rft_id=info:doi/10.1007%2Fs00280-023-04504-z&rft_id=info%3Apmid%2F36707434&rft.externalDocID=PMC9905199
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon